TDSPharm Co

TDSPharm Co Div.-Adj. PEG

The Dividend-Adjusted PEG Ratio of TDSPharm Co (464280.KQ) as of Oct 31, 2026 is 1.62. In the previous year, Dividend-Adjusted PEG Ratio was 1.86 — a change of -13.02% (lower).

Div.-Adj. PEG

1.62

YoY

-13.02%

Last updated:

Dividend-Adjusted PEG Ratio of TDSPharm Co is 2025 1.62 . Dividend-Adjusted PEG Ratio of TDSPharm Co was 2024 1.86 . It decreases by -13.02% lower compared to the previous year.

The TDSPharm Co Div.-Adj. PEG history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Div.-Adj. PEG
Date
Div.-Adj. PEG
Jan 1, 2021
3.35 KRW
Jan 1, 2022
2.00 KRW
Jan 1, 2023
1.47 KRW
Jan 1, 2024
1.86 KRW
Jan 1, 2025
1.62 KRW
The TDSPharm Co Div.-Adj. PEG history
YEARDiv.-Adj. PEGYoY
1.62-13.02%
1.86+26.09%
1.47-26.29%
2.00-40.30%
3.35—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TDSPharm Co Stock analysis

What does TDSPharm Co do? TDSPharm Co Ltd generates revenue through the manufacture and sale of synthetic drug displays and other finished drugs, as well as medical equipment sales. The company operates in the pharmaceutical manufacturing sector with a focus on synthetic drug displays and finished pharmaceutical products. Its e-commerce business complements traditional sales channels for medical equipment and pharmaceuticals. The primary customers include healthcare providers, hospitals, and medical institutions purchasing synthetic drug displays, finished drugs, and medical equipment. The company's product segments are synthetic drug displays, finished drugs, and medical equipment, with e-commerce serving as an additional sales channel for these segments. TDSPharm Co Ltd's revenue streams are derived from three core product categories: synthetic drug displays, finished drugs, and medical equipment. The company's e-commerce platform facilitates direct sales to healthcare institutions and medical facilities. The business model combines traditional manufacturing with digital sales channels, targeting healthcare providers as the main customer segment. The company's operations are centered on pharmaceutical manufacturing and medical equipment distribution, with e-commerce as a supplementary sales method. The company's primary revenue comes from the sale of synthetic drug displays and finished drugs, which are manufactured and sold directly to healthcare institutions. Medical equipment sales form a secondary revenue stream, while the e-commerce business provides an additional channel for all product categories. TDSPharm Co Ltd targets healthcare providers and medical institutions as its main customer base, with product segments focused on pharmaceutical manufacturing and medical equipment distribution. TDSPharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TDSPharm Co stock

Dividend-Adjusted PEG Ratio of TDSPharm Co is 1.62 in 2025.

Dividend-Adjusted PEG Ratio of TDSPharm Co changed from 1.86 to 1.62, representing a -13.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Dividend-Adjusted PEG Ratio TDSPharm Co since 2006 – with annual values, charts, and detailed analysis.

The dividend-adjusted PEG ratio factors in dividend yield alongside earnings growth, providing a more complete valuation for income-paying stocks.

To evaluate Dividend-Adjusted PEG Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Dividend-Adjusted PEG Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Dividend-Adjusted PEG Ratio's TDSPharm Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — TDSPharm Co

All Key Metrics — TDSPharm Co